mHealth Intelligence September 15, 2023
Healthcare providers urged the DEA to allow virtual prescribing of controlled substances without in-person requirements, advocating for streamlined regulations.
At the United States Drug Enforcement Agency’s (DEA) listening sessions on September 12 and 13, healthcare stakeholders argued for permanently extending pandemic-era telehealth prescribing flexibilities for controlled substances.
During the COVID-19 pandemic, the DEA waived rules outlined in the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 that required healthcare practitioners to conduct an in-person medical evaluation before allowing them to prescribe controlled substances through telehealth.
In February, the DEA released proposed rules stating that providers would only be allowed to virtually prescribe a 30-day supply of Schedule III-V non-narcotic controlled medications and a 30-day supply of buprenorphine for...
Today's Sponsors
Today's Sponsor